Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 280.68M P/E - EPS this Y 1.90% Ern Qtrly Grth -
Income -104.07M Forward P/E -2.04 EPS next Y -11.70% 50D Avg Chg -11.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -51.00%
Dividend N/A Price/Book 0.70 EPS next 5Y - 52W High Chg -72.00%
Recommedations 1.80 Quick Ratio 14.85 Shares Outstanding 48.81M 52W Low Chg 19.00%
Insider Own 7.16% ROA -16.78% Shares Float 31.36M Beta -0.06
Inst Own 92.85% ROE -31.10% Shares Shorted/Prior 4.37M/5.78M Price 5.75
Gross Margin - Profit Margin - Avg. Volume 765,678 Target Price 30.80
Oper. Margin - Earnings Date Mar 15 Volume 443,073 Change -0.86%
About Nkarta, Inc.

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Nkarta, Inc. News
01/09/23 Nkarta Promotes David R. Shook, M.D., to Chief Medical Officer
12/05/22 Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
12/02/22 Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX019 NK Cell Therapy Program
11/09/22 Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights
11/07/22 Nkarta Presents Data Supporting Engineered NK Cell Based Combination Therapies and Next Generation Commercial-Scale Manufacturing Platform at SITC 37th Annual Meeting
11/02/22 Nkarta to Participate at Upcoming Investor Conferences
09/24/22 Companies Like Nkarta (NASDAQ:NKTX) Are In A Position To Invest In Growth
09/23/22 7 Unknown Biotech Stocks That Could Rocket in 2023
08/11/22 Nkarta Reports Second Quarter 2022 Financial Results and Corporate Highlights
08/10/22 Should You Buy Nkarta (NKTX) Ahead of Earnings?
08/07/22 Over 100% Upside: Analysts See an Appealing Entry Point in These 3 ‘Strong Buy’ Stocks
07/25/22 Nkarta Announces Key Senior Leadership Team Appointments
07/18/22 SVB Leerink Picks This Well-Positioned NK Cell-Focused Stock, Sees 117% Upside
06/14/22 What Is The Ownership Structure Like For Nkarta, Inc. (NASDAQ:NKTX)?
06/07/22 Wall Street Analysts Predict a 209% Upside in Nkarta, Inc. (NKTX): Here's What You Should Know
05/31/22 Nkarta to Participate at Upcoming Investor Conference
05/18/22 What Makes Nkarta, Inc. (NKTX) a New Buy Stock
05/18/22 Can Nkarta, Inc. (NKTX) Climb 383% to Reach the Level Wall Street Analysts Expect?
05/16/22 Nkarta Appoints David R. Shook, MD, as Vice President, Clinical Development
05/12/22 Nkarta Reports First Quarter 2022 Financial Results and Corporate Highlights
NKTX Chatroom

User Image Quantisnow Posted - 4 hours ago

$NKTX 📜 SEC Form SC 13G filed by Nkarta Inc. https://quantisnow.com/i/4003537?utm_source=stocktwits 45 seconds delayed.

User Image Newsfilter Posted - 4 hours ago

$NKTX Form SC 13G (statement of acquisition of beneficial ownership by individuals) filed with the SEC https://newsfilter.io/a/a87d585d4e7b703359ba96fb1f27a917

User Image Marcink83 Posted - 1 day ago

$NKTX not bad return in few days

User Image WizardsSleeve Posted - 2 days ago

$NKTX Not bad eh, @LabPsycho ?

User Image Marcink83 Posted - 2 days ago

$NKTX rally mode soon

User Image WizardsSleeve Posted - 2 days ago

$NKTX

User Image TickerDD_com Posted - 2 days ago

From 1/27/2023, looking back across 22 Month-Ends for NKTX, Percentage Change of Average Monthly Price had More Negatives (55%) while Percentage Change of Average Monthly Volume had More Positives (95%) $NKTX #NKTX #NKTXStock #TickerDD #NKTXNews https://www.youtube.com/watch?v=g9WMWD2Zf5A

User Image Sir_1 Posted - 01/31/23

$NKTX More Data will be rolled out in the second half. Definitely adding

User Image GeorgeTheo Posted - 01/31/23

$SLS $SNDX $KURA $NKTX $VINC LabPsycho - its why SLS is the place to Be DD on GPs and GFH009 Love to hear your thoughts Car T doesn't work for AML either.

User Image LabPsycho Posted - 01/31/23

$NKTX @GeorgeTheo Nice post / reasonable comps. My hesitation with getting into NKTX at this price is, as I have been stating for over a year now, 1. I do not like CAR-T and think the lymphodepletion step alone can explain some of the stellar, albeit transient responses seen in many phase 1 CAR-T trials. 2. Sooooo many companies doing CAR-T, so it is certain many will go under or merge with the larger / stonger CAR-T biotechs that have had good news past several months (ie. partnership announcements) 3. Recent bad news in other CAR-T companies (i.e. $FATE) pulling many in this sector down - however that may also be the best time to buy other beaten down CAR-T companies like NKTX. 4. I would like to see a capitulation indicator on NKTX..where those who have ridden the stock down for months just give up and throw in the towel...I think we could be close here but wont buy until it gets into the $4's. Good luck.

User Image GeorgeTheo Posted - 01/30/23

$SLS GFH009 Market Comps $VINC once had a Mkt Cap of $600M with just one asset; A Ph 1 trial showing efficacy for AML R/R patients -VIP150 a 'selective' CDK9 Inhibitor - the potential was worth $600M --- GFH 009 is under appreciated. $SNDX a menin Inhibitor 30%C r Rate, 70% of them MRD- in a PH1 Trial MKT Cap $2B. $KURA $1B Mkt Cap again Menin inhibitor for KTMA NPMa Mutant AML R/R subsets with again a 30% Cr rate in a P1 \ data measured in DAYs GFH009 Final 80 patient AML R/R results are imminently due. the previous dose dependent data 30mg, ie more efficacious w increased dosage had 50% CR or Stable disease. - Final 40, 45, and 60mg results due $NKTX added $600M mcap in one day last year on a 5 patient AML r/r cohort Ph 1 readout. https://www.bloomberg.com/press-releases/2022-12-13/sellas-announces-positive-phase-1-data-with-cdk9-inhibitor-gfh009-monotherapy-in-patients-with-relapsed-refractory-hematologic

User Image Marcink83 Posted - 01/30/23

$NKTX great fundamentals

User Image LabPsycho Posted - 01/30/23

$NKTX My opinion -Downward pressures on stock: If 92% owned by institutions, what is going to happen to NKTX when investors in said institutions start / continue to withdraw $$ from their accounts? And now that it is below $5, institutions with $5 restrictions will have to sell. So, in your opinion what are the forces that will make NKTX go up..other than technical bounce?

User Image Marcink83 Posted - 01/30/23

$NKTX starter here. Will be adding pullbacks in tranches. Swing. Insiders dropped serious cash last year totaling $53M at $15 per share! Institutional ownership nearly 92%. Average PT by 12 analysts $30…hopefully near its bottom. Good luck!

User Image LabPsycho Posted - 01/28/23

$NKTX I think the time to buy will be after a lull in the volume for about 4-6 weeks and stock price plateau in the 4's. One additional Buy indicator for me is when the posts on this board dry up = many have given up on the stock. Good luck

User Image johnmilnes Posted - 01/26/23

$NKTX starter 5.03, breaks support ill stop out

User Image babajan1 Posted - 01/25/23

$NKTX MMs

User Image WizardsSleeve Posted - 01/25/23

$NKTX

User Image vatexas Posted - 01/24/23

$NKTX Bought a starter today

User Image WizardsSleeve Posted - 01/24/23

$NKTX Let's get the guys paid already, NKTX.....Been long enough now. Congrats longs.

User Image mrshort Posted - 01/23/23

$NKTX Estimated S.I as on 1/20/23 14.77 Percent Please complete information please join me via stocktwits.com/mrshort, for stock alerts, news, chat rooms, squeeze ranking watchlist. We are consistency hitting profit with our trading strategy. NKTX has Institutional ownership of 57.94% and inside ownership of 0.65% Analyst rating 3.78 and Long Term Debt/ Capital 100.20% Our members daily updated information of highly shorted stock, squeeze ranking, access to Chat rooms, IPO analysis, Daily watchlist, Market Watchlist.Catalyst.

User Image StocktwitsTester Posted - 01/23/23

$NKTX cheap

User Image Alejos11 Posted - 01/22/23

Tomorrow’s watchlist2 $COSM $CCO $NKTX $PYPD $BIOL

User Image macroaxis Posted - 01/22/23

$NKTX - Volatility alert: NkartaInc options pin risk is increasing https://www.macroaxis.com/stock-options/NKTX/NkartaInc?utm_source=dlvr.it&utm_medium=stocktwits

User Image LabPsycho Posted - 01/22/23

$NKTX @CatalystInvestments Hmm...I dont know...upper $3's maybe but I almost feel its bottomed out here for a while...however the easy 10% bounce is behind us.

User Image LabPsycho Posted - 01/22/23

$FATE $NKTX @Luckyskills007 Interesting perspective and I agree - typically one develops a technology to the point where they know it won't work, and then they license it. LoL. So if one is willing to turn down some seemingly big bucks in this tough fiscal environment it may adumbrate something positive in the future.?

User Image Profitable987 Posted - 01/21/23

$NKTX reversal play....

User Image TradeAlertsTeam Posted - 01/20/23

🚨Unusual Volume🚨 Part 1 $NKTX $SCLX $CYT $MARK $STRO Stay tune for more ideas!

User Image Alejos11 Posted - 01/20/23

$NKTX potential bottom is in play

User Image CatalystInvestments Posted - 01/20/23

$NKTX waiting for $3s if possible. I'm sure there will be some sort of calamity sinking biotech again in 2023.

Analyst Ratings
Oppenheimer Perform Dec 22, 22
Mizuho Buy Nov 16, 22
Oppenheimer Outperform Nov 10, 22
Cantor Fitzgerald Overweight Aug 12, 22
Needham Buy Jul 28, 22
SVB Leerink Outperform Jul 18, 22
Raymond James Outperform Apr 26, 22
HC Wainwright & Co. Buy Apr 26, 22
Raymond James Outperform Mar 11, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Trager James Chief Scientific Off.. Chief Scientific Officer Jan 13 Sell 5.49 1,115 6,121 98,557 01/18/23
Shook David Chief Medical Office.. Chief Medical Officer Jan 13 Sell 5.49 175 961 60,302 01/18/23
Mahmood Nadir See Remarks See Remarks Jan 13 Sell 5.49 1,122 6,160 84,302 01/18/23
HASTINGS PAUL J Chief Executive Offi.. Chief Executive Officer Jan 13 Sell 5.49 3,691 20,264 313,106 01/18/23
Hager Alicia J. Chief Legal Officer Chief Legal Officer Jan 13 Sell 5.49 1,103 6,055 57,197 01/18/23
Brandenberger Ralph Chief Technical Offi.. Chief Technical Officer Jan 13 Sell 5.49 491 2,696 28,309 01/18/23
Trager James Chief Scientific Off.. Chief Scientific Officer Aug 15 Option 3.89 5,000 19,450 67,172 08/17/22
Trager James Chief Scientific Off.. Chief Scientific Officer Aug 15 Sell 17.53 5,000 87,650 62,172 08/17/22
Brandenberger Ralph Chief Technical Offi.. Chief Technical Officer Aug 15 Option 3.89 11,000 42,790 18,800 08/17/22
Brandenberger Ralph Chief Technical Offi.. Chief Technical Officer Aug 15 Sell 17.64 11,000 194,040 7,800 08/17/22
Mahmood Nadir See Remarks See Remarks Aug 15 Option 3.89 7,500 29,175 53,588 08/17/22
Mahmood Nadir See Remarks See Remarks Aug 15 Sell 18.03 7,500 135,225 46,088 08/17/22
Brandenberger Ralph Chief Technical Offi.. Chief Technical Officer Aug 08 Option 3.02 11,593 35,011 19,393 08/10/22
Brandenberger Ralph Chief Technical Offi.. Chief Technical Officer Aug 08 Sell 15.51 11,593 179,807 7,800 08/10/22
Mahmood Nadir See Remarks See Remarks Aug 08 Option 3.89 7,500 29,175 53,588 08/10/22
Mahmood Nadir See Remarks See Remarks Aug 08 Sell 15.32 7,500 114,900 46,088 08/10/22
Brandenberger Ralph Chief Technical Offi.. Chief Technical Officer Jul 25 Option 0.41 3,000 1,230 10,800 07/26/22
Brandenberger Ralph Chief Technical Offi.. Chief Technical Officer Jul 25 Sell 13.41 3,000 40,230 7,800 07/26/22
Mahmood Nadir See Remarks See Remarks Jul 25 Option 3.89 7,500 29,175 53,588 07/26/22
Mahmood Nadir See Remarks See Remarks Jul 25 Sell 13.4 7,500 100,500 46,088 07/26/22
George Simeon Director Director Apr 28 Buy 15 1,333,333 19,999,995 666,666 04/29/22